Oregano Oil for Health & Longevity - Quick Reference Sheet

Oregano Oil for Health & Longevity

Created on 08/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Oregano oil kills bacteria and fungi in the laboratory, but human evidence is far thinner: a few small studies, mostly without comparison groups, suggest it clears gut organisms. Against that sit burning and stomach upset, skin irritation when undiluted, laboratory signs it may speed liver drug clearance like St John's wort, and most tested products far below their claimed potency. (Full Review)

Protocol

Standard oral regimen
100–200 mg, one to three times daily
Standardised to at least 55–70% carvacrol, with food, for 2–4 weeks; roughly 60–120 mg carvacrol per day
Best time of day
With the largest meals
Or 30 minutes pre-meal on an empty stomach when the target is gastric colonisation; not within three hours of bedtime
Single versus split dosing
Split
Divided dosing keeps each mucosal exposure below the irritation threshold; every human protocol that reported benefit used two or three daily doses
Time to effect
Intestinal protozoa clearance
6 weeks
Documented organism clearance in the parasite study
Helicobacter pylori clearance
45–60 days
Documented organism clearance in the Helicobacter pylori series
Gastrointestinal symptom change
Days to two weeks
Symptom impression alone does not confirm organism clearance

Benefits

Contraindications
  • Pregnancy at any gestational stage, trying to conceive, breastfeeding
  • Known allergy or prior systemic reaction to any Lamiaceae plant (oregano, thyme, basil, marjoram, sage, mint, lavender, hyssop)
  • Active peptic ulcer disease, or erosive oesophagitis at Los Angeles grade C or D
  • Children under 2 years (oral use), under 12 years (undiluted topical use)
  • Iron-deficiency anaemia or ferritin below 30 ng/mL, until corrected
  • Solid-organ transplant recipients, or narrow-therapeutic-index drugs (tacrolimus, ciclosporin, warfarin, phenytoin, antiretroviral HIV medicine) unless levels are monitored
  • Within 14 days of elective surgery
Key Interactions
  • CYP3A4 substrates (simvastatin, atorvastatin, tacrolimus, ciclosporin, apixaban, rivaroxaban)
  • CYP1A2 substrates (caffeine, theophylline, clozapine, olanzapine, tizanidine, melatonin)
  • CYP2A6 substrates (nicotine, letrozole, coumarin-containing products)
  • UGT1A9 substrates (propofol, mycophenolate)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin)
  • Over-the-counter drugs (NSAIDs, aspirin, caffeine tablets)
  • Over-the-counter acid suppressants (omeprazole, famotidine)
  • Supplement interactions (St John's wort, berberine, garlic, allicin, thyme and savory oils)
  • Supplements with additive effects: blood-glucose-lowering botanicals (berberine, bitter melon, chromium, cinnamon extract)
  • Probiotics and iron supplements
  • Other interventions: antibiotic courses and elemental diet for bacterial overgrowth

Risk & Side Effects

  • High: Gastrointestinal burning, pain and nausea with oral use; skin and mucous membrane irritation from undiluted topical use
  • Medium: Herb–drug interactions through drug-metabolising enzyme induction; under-dosed, overstated or adulterated products
  • Low: Allergic reactions and cross-reactivity within the mint family; falls in iron status and HDL cholesterol; suppression of beneficial gut bacteria
  • Speculative: Pregnancy loss and developmental toxicity; additive blood-sugar lowering; liver injury; additive bleeding risk with anticoagulant and antiplatelet drugs

Monitoring

Marker Target Why
Ferritin 50–150 ng/mL Iron stores; carvacrol dosing lowered serum iron in the only formal safety trial
Serum iron and transferrin saturation Transferrin saturation 25–35% Detects the specific fall seen at 2 mg/kg/day carvacrol before ferritin moves
Haemoglobin and haematocrit Haemoglobin 13.5–15.0 g/dL (men), 12.5–14.5 g/dL (women) Red-cell count and haematocrit both declined during sustained carvacrol dosing
HDL cholesterol Above 55 mg/dL (men), above 65 mg/dL (women) The one lipid marker with directly conflicting evidence — up with whole oil, down with purified carvacrol
ALT and GGT ALT below 20 U/L (men), below 17 U/L (women); GGT below 20 U/L Screens for liver injury from concentrated botanical oils
hs-CRP Below 0.5 mg/L The inflammatory marker most likely to move if the anti-inflammatory signal is real
Lactulose or glucose breath test Normalisation: no rise above 20 parts per million of hydrogen within 90 minutes Defines whether bacterial overgrowth actually cleared
Stool pathogen and parasite panel Negative result on repeat testing The endpoint used in the parasite study, and the only objective proof of clearance
Narrow-therapeutic-index drug levels (tacrolimus, ciclosporin, phenytoin, clozapine) Each drug's own established therapeutic window Detects the enzyme induction predicted by laboratory data before clinical failure occurs

Cadence: Baseline before starting; tolerability reviewed at one week; narrow-therapeutic-index drug levels at four weeks and again 2–4 weeks after stopping; confirmatory test, iron measures and lipids repeated at the end of the course; iron status and liver enzymes every 6–12 months if pulsed cycles continue.

Qualitative Assessment

  • Bloating, abdominal distension and stool form, recorded daily rather than recalled
  • Reflux, burning or the characteristic heated sensation, which signals dose or formulation is wrong
  • Energy through the afternoon, the symptom most often reported as improving in gut-targeted use
  • Skin appearance and any itch or redness, particularly with topical application
  • Sleep continuity, as an indirect readout of night-time reflux
  • Cognitive clarity and mood, both commonly reported but never formally measured in any oregano oil trial